Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.36 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | STS | P08842 | 3/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668992 | 1.00 | NR1I2 (0.42) | NR1I2MEN1KMT2ACYP2E1GPR119 | |
| SCHEMBL138216 | 0.90 | NR1I2 (0.53) | NR1I2MEN1KMT2ACYP2E1GPR119 | |
| SCHEMBL138217 | 0.90 | NR1I2 (0.53) | NR1I2MEN1KMT2ACYP2E1GPR119 | |
| SCHEMBL12514487 | 0.86 | MEN1 (0.42) | NR1I2MEN1KMT2AGPR119EED | |
| SCHEMBL2216688 | 0.86 | NR1I2 (0.51) | NR1I2MEN1KMT2ACYP2E1GPR119 | |
| SCHEMBL15498399 | 0.85 | NR1I2 (0.38) | NR1I2MEN1KMT2ACYP2E1ALDH1A1 | |
| SCHEMBL15499605 | 0.85 | NR1I2 (0.38) | NR1I2MEN1KMT2ACYP2E1ALDH1A1 | |
| SCHEMBL15498330 | 0.85 | NR1I2 (0.41) | NR1I2CYP2E1 | |
| SCHEMBL15511698 | 0.85 | NR1I2 (0.41) | NR1I2CYP2E1 | |
| SCHEMBL10206095 | 0.85 | NR1I2 (0.41) | NR1I2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2606041-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024363-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | GOT1, RNASE1, SLC10A1 | NR1I2 1347/4885MEN1 4453/4885KMT2A 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.